ConcertAI and Foundation Medicine Combine Data Assets to Create Large-Scale Clinico-Genomic Oncology Dataset

ConcertAI and Foundation Medicine have announced a strategic collaboration to integrate their respective data platforms, creating a large-scale clinico-genomic dataset representing nearly half a million cancer patients. The combined resource is intended to provide life sciences researchers with a more comprehensive, longitudinal view of the cancer patient journey, from pre-diagnosis through treatment and long-term outcomes.

The collaboration brings together Foundation Medicine’s de-identified multimodal genomic testing data with ConcertAI’s curated real-world clinical records. According to the companies, this integration is designed to address growing challenges in oncology research, including increasing trial complexity, constrained development budgets, and the need for clearer evidence earlier in drug development programs.

The resulting dataset extends beyond traditional genomic sequencing by incorporating multiple data modalities. It includes FDA-approved diagnostic signatures and hard-to-detect genomic alterations, such as MTAP loss, which may not be consistently identified through standard next-generation sequencing approaches. In addition, the dataset integrates whole-slide imaging, gene expression data, and immunohistochemistry results, enabling researchers to examine tumor biology using both molecular and visual data sources.

ConcertAI contributes clinical depth through one of the industry’s broader real-world oncology datasets, encompassing patients across diverse socioeconomic backgrounds, ethnic groups, and geographic settings, including both rural and urban populations. This breadth is intended to support analyses that better reflect real-world patient experiences and outcomes, rather than relying solely on controlled clinical trial populations.

A central objective of the partnership is to accelerate the “test-to-treatment” pipeline by helping biopharmaceutical companies establish more focused research strategies. By linking early genomic signals with longitudinal clinical outcomes, the companies aim to enable researchers to better understand disease progression and treatment response over time, particularly for targeted therapies.

“Drug developers are increasingly pushed to accelerate their research pipelines but require more robust insights into both early genomic signals and patient outcomes to make this a reality,” said Eron Kelly, CEO of ConcertAI. “By combining the largest and deepest set of clinical data with genomic insights, including whole slide imaging, we can help teams set a clearer plan and speed up their projects. Our collaboration with Foundation Medicine complements our full suite of partnerships aimed at advancing the development of vital therapies.”

The companies stated that the integrated dataset is intended to support oncology research and development efforts across discovery, translational research, and clinical development, with a focus on improving decision-making through more complete real-world evidence.

Click here for the original news story.